Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn

Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth around $4.9 billion to acquire Forty Seven, ... Read More